Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005 (Hep C Chronic Fatigue)

Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005
[Press Release] PR Newswire via Yahoo! Finance - Feb 09 6:38 AM
Human Genome Sciences, Inc. announced financial results for the quarter and full-year periods ended December 31, 2005, and reiterated guidance for financial results anticipated for 2006.Save to My Web

Hepatitis C Recurs Rapidly After Liver Transplant
Science Daily - Feb 06 3:41 PM
When a diseased liver is removed from a patient with Hepatitis C (HCV), serum viral levels plummet. However, after receiving a healthy liver transplant, virus levels rebound and can surpass pre-transplant levels within a few days, according to a new study.Save to My Web

Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For The Treatment Of Patients With Chronic Hepatitis
Medical News Today - Feb 12 8:09 PM
Novartis and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide... click link for more info.Save to My Web

YOU ARE HERE:
Aidsmap - Feb 17 4:58 AM
Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two studies presented last week at the Thirteenth Conference on Retroviruses and Opportunistic Infections in Denver.Save to My Web